Intra-Cellular Therapies Appoints Professor Sir Michael Rawlins to its Board of Directors

 Intra-Cellular Therapies Appoints Professor Sir Michael Rawlins to its Board
                                 of Directors

PR Newswire

NEW YORK, May 14, 2013

NEW YORK, May 14, 2013 /PRNewswire/ --Intra-Cellular Therapies, Inc. ("ITI"),
a biopharmaceutical company focused on the development of therapeutics for CNS
disorders, is pleased to announce the appointment of Professor Sir Michael
Rawlins, MD, FRCP, FMedSci, to its board of directors. Sir Michael is an
internationally respected figure in the field of drug safety, clinical
effectiveness and cost effectiveness having been Chairman of the UK's National
Institute for Clinical Excellence (NICE) from 1999 (at its inception) through
March 2013. NICE provides guidance to the UK's National Health Service (NHS)
on whether new or existing pharmaceutical products should be made available to
patients covered under the NHS and also develops clinical guidelines for
patient care by NHS professionals. Recently, Sir Michael assumed the
Presidency of the UK's Royal Society of Medicine, a center for education and
scholarship both in the UK and globally. Sir Michael had a distinguished
career as professor of clinical pharmacology and a general physician at the
University of Newcastle upon Tyne. He is the recipient of numerous honors
over the years, such as the Hutchinson Medal in 2003, the Galen Medal in 2010,
and the Prince Mahidol Award for Medicine in 2012. He was appointed Knight
Bachelor in 1999.

"We are excited to have Sir Michael Rawlins join our board," stated Sharon
Mates, Ph.D., Chairman and Chief Executive Officer of Intra-Cellular
Therapies. "His expertise in the cost-effectiveness of new pharmaceuticals
and other issues in health economics will be invaluable to Intra-Cellular
Therapies. I look forward to working closely with Michael as we transition
our clinical programs through late-stage development and commercial approval."

"I am delighted to join the ITI Board of Directors. It comprises a group of
individuals who have made significant contributions to the advancement of
medical science, biotech entrepreneurship and the development of drugs serving
unmet medical needs," said Sir Michael. "ITI has set itself on a course to
develop outstanding new pharmaceuticals to treat CNS diseases, surely an
ambitious task, but one in which I am pleased to join and help."


ITI-007 is the Company's first-in-class antipsychotic with a unique mechanism
of action. ITI-007 combines potent 5-HT2A receptor antagonism with dopamine
receptor phosphoprotein modulation (DPPM) and serotonin reuptake inhibition
for the treatment of acute and residual schizophrenia. At dopamine D2
receptors, ITI-007 has dual properties acting as a post-synaptic antagonist
and as a pre-synaptic partial agonist. ITI-007 also stimulates
phosphorylation of glutamatergic NMDA NR2B receptors in a mesolimbic specific
manner. This regional selectivity in brain areas thought to mediate the
efficacy of antipsychotic drugs together with serotonergic, glutamatergic, and
dopaminergic interactions is expected to result in superior antipsychotic
efficacy for positive, negative, affective and cognitive symptoms associated
with schizophrenia.The serotonin reuptake inhibition allows for additional
antidepressant efficacy for the treatment of schizoaffective disorder,
co-morbid depression, and/or as a stand-alone treatment for major depressive
disorder (MDD). ITI-007 is currently in a Phase II clinical trial in
schizophrenia. We believe ITI-007 will be useful for the treatment of
behavioral disturbances in dementia, autism and other CNS diseases and well as
in bipolar disorder and other psychiatric and neurodegenerative disorders.


Intra-Cellular Therapies (ITI) is developing novel drugs for the treatment of
neuropsychiatric and neurodegenerative disease and other disorders of the
Central Nervous System (CNS). The Company is studying the efficacy of ITI-007
for the treatment of acutely-exacerbated schizophrenia in a large Phase II,
multicenter clinical trial. This Phase II trial follows a favorable Phase
I/II study demonstrating the safety and tolerability of ITI-007 across a broad
range of doses in patients with stable schizophrenia. In the Phase I/II
trial, exploratory clinical measures revealed signals consistent with
antipsychotic efficacy for positive and negative symptoms and antidepressant
efficacy for ITI-007.In February 2011, ITI entered into a collaboration with
the Takeda Pharmaceutical Company to develop phosphodiesterase 1 (PDE1)
inhibitors for the treatment of cognitive deficits in schizophrenia and other
CNS disorders. Recently, ITI announced the successful completion of a Phase I
single rising dose study of its PDE1 inhibitor, ITI-214. ITI has additional
programs in the areas of Parkinson's disease, Alzheimer's disease, depression,
and cardiovascular disease.

Allen A. Fienberg, Ph.D.
Vice President
Business Development of Intra-Cellular Therapies, Inc.

Burns McClellan, Inc.
Angeli Kolhatkar (Investors)
Justin Jackson (Media)
Phone +1 (212) 213-0006

SOURCE Intra-Cellular Therapies, Inc.

Press spacebar to pause and continue. Press esc to stop.